EGFR and breast carcinoma: For instance, TMEM25 inhibits EGFR-driven STAT3 activation in triple-negative breast cancer, and TMEM116 is crucial for lung cancer cell mobility and metastasis via the PDK1 pathway.29, 30 TMEM9A promotes breast cancer progression by activating the Wnt/β-Catenin pathway.31